Lino Biotech

Executive Summary

Lino Biotech AG, a Swiss biotech subsidiary of Miltenyi Biotec, specializes in label-free biosensing platforms based on its proprietary focal molography technology. This innovation enables real-time, quantitative measurement of molecular interactions directly in complex biological samples such as crude media or plasma, eliminating the need for purification. The platform is primarily applied in drug discovery, including hit validation from DNA-encoded libraries (DEL) and SELEX screens, as well as binder development for antibodies and aptamers, and target identification for membrane proteins like GPCRs. By providing rapid, label-free kinetic data in physiologically relevant conditions, Lino's technology addresses key bottlenecks in early-stage drug development, potentially accelerating candidate selection and reducing attrition.

Upcoming Catalysts (preview)

• Q4 2026Commercial launch of next-generation molography instrument70% success
• Q2 2026Key partnership with a top-20 pharma company for DEL hit validation60% success
• Q3 2026Publication of validation data in a high-impact journal demonstrating GPCR target identification80% success